CELSENSE, INC.

Pittsburgh, PA · Founded 2005 · Medtech · Defunct

Perfluorocarbon (PFC) nanoemulsion MRI imaging probes with cell-penetrating peptides for visualizing cell therapy biodistribution

Claim this profile

Follows are private to you and power your alerts

Updated Oct 23, 2026 · celsense.com

Sector: Medtech
Headquarters: Pittsburgh, PA
Founded: 2005
Latest Form D: $500K offered, Feb 2020
Total capital: $5.3M

Federal grants: $2.8M; 4 awards · 2018–2020; Rank in peer group#29 of 41
Private capital raised: $2.5M; 10 Form D · last Feb 2020; 81 months since last filing
Federal contracts: None on recordNo federal contract awards found.
Granted patents: 1; 5 pending · first 2016; Rank in peer group#13 of 41

Capital timeline

Latest events

Sep 2020Federal grantHealth and Human S · Phase I · Functionalized perfluorocarbon nanoemulsions for enhanced cell labeling for fluorine-19 MRI detection$225K
Apr 2020Federal grantHealth and Human S · Phase II · Product for sensitive imaging of cells in vivo$707K
Feb 2020Offering registeredForm D · SEC · 10th filing$500K
May 2019Federal grantHealth and Human S · Phase II · Product for sensitive imaging of cells in vivo$1.5M
Jun 2018Federal grantHealth and Human S · Phase I · Product for sensitive imaging of cells in vivo$341K
May 2018Private capital raisedForm D · SEC · 9th filing$125K
Aug 2016Private capital raisedForm D · SEC · 8th filing$100K
Dec 2015Private capital raisedForm D · SEC · 7th filing$248K
Sep 2014Private capital raisedForm D · SEC · 6th filing$268K
Oct 2013Offering registeredForm D · SEC · 5th filing$1M
Feb 2012Private capital raisedForm D · SEC · 4th filing$125K
May 2010Private capital raisedForm D · SEC · 3rd filing$684K
Apr 2010Private capital raisedForm D · SEC · 2nd filing$150K
Jun 2009Private capital raisedForm D · SEC · 1st filing$761K

Node area is scaled to amount. Form D reports securities sold, which can differ from an announced round; filings are numbered in the order they were made.

Standing among 41 peers

Line = median

Medtech · Molecule

Federal grantsBelow median
Granted patents#13 · top 32%

Cumulative measures favor older companies. Rankings describe position today, not outcome. Below the median, ranks show as a band rather than a number.

Founders and team

Researcher links verified by same-company patents and grants

Eric T. AhrensResearcherDirectorLinked by 1 patent
Charles F O'HanlonResearcherExecutive Officer, DirectorLinked by $341K in grants as PI
Charles F. O'Hanlon, IIIExecutive Officer, DirectorNamed in SEC Form D filings
Daniel P GallagherDirectorNamed in SEC Form D filings
Daniel P. Gallagher, Jr.DirectorNamed in SEC Form D filings
D. Lansing TaylorDirectorNamed in SEC Form D filings

Show all 19 people

Eric T. AhernsDirectorNamed in SEC Form D filings
Gerald L. TarantinoDirectorNamed in SEC Form D filings
Gregory T. HebrankDirectorNamed in SEC Form D filings
Jeffrey S. FriedmanDirectorNamed in SEC Form D filings
Kevin S. McClatchyDirectorNamed in SEC Form D filings
Lourdes M. CastellanosExecutive OfficerNamed in SEC Form D filings
L Gerald TarantinoDirectorNamed in SEC Form D filings
L. Gerald TarantinoDirectorNamed in SEC Form D filings
Paul L. KornblithDirectorNamed in SEC Form D filings
Ronald B. HerbermanExecutive Officer, DirectorNamed in SEC Form D filings
T. Ronald CasperExecutive OfficerNamed in SEC Form D filings
Thomas T PetzingerDirectorNamed in SEC Form D filings
Thomas T. Petzinger, Jr.DirectorNamed in SEC Form D filings

What it has protected

USPTO · 1 granted of 6

Oct 13, 2016PendingCompositions and Methods to Image and Quantify InflammationUSPTOApplication 14783684
Aug 18, 2016PendingCompositions and Methods to Image and Quantify InflammationUSPTOApplication 15043004
May 31, 2016GrantedCompositions And Methods For Producing Emulsions For Nuclear Magnetic Resonance Techniques And Other ApplicationsUSPTOUS 9,352,057

Show all 6 patent records

Compositions and Methods to Image and Quantify InflammationOct 13, 2016 · Application 14783684Pending
Compositions and Methods to Image and Quantify InflammationAug 18, 2016 · Application 15043004Pending
Compositions And Methods For Producing Emulsions For Nuclear Magnetic Resonance Techniques And Other ApplicationsMay 31, 2016 · US 9,352,057Granted
Compositions And Methods To Image And Quantify InflammationApplication PCTUS2014052685Pending
Compositions And Methods For Producing Emulsions For Nuclear Magnetic Resonance Techniques And Other ApplicationsApplication PCTUS2009002706Pending
Methods For Assessing Cell LabelingApplication PCTUS2007009392Pending

SEQUELASimilar federal contract value in Medtech · null in contracts
Nanox Imaging plc.Similar federal contract value in Medtech · null in contracts
ASC Rodgers Park LLCSimilar federal contract value in Medtech · null in contracts
DASISIMULATIONS LLCSimilar federal contract value in Medtech · null in contracts
TREYSTA MEDICAL TECHNOLOGIES INCSimilar federal contract value in Medtech · null in contracts
QUARKSEN LLCSimilar federal contract value in Medtech · null in contracts

Regulatory activity · Medtech

Sector-level, not company-level

07 Jul 2026New Animal Drugs; Approval of New Animal Drug Applications; Withdrawal of Approval of New Animal Drug Application; Change of SponsorFood and Drug Administration
30 Jun 2026Medical Devices; General and Plastic Surgery Devices; Classification of the Skin Patch for Treatment of HyperhidrosisFood and Drug Administration
30 Jun 2026Medical Devices; Anesthesiology Devices; Classification of the Monitor for Opioid Induced Impairment of OxygenationFood and Drug Administration
29 Jun 2026Medical Devices; Orthopedic Devices; Classification of the Medial Knee Implanted Shock AbsorberFood and Drug Administration
26 Jun 2026Medical Devices; Neurological Devices; Classification of the External Lower Extremity Nerve Stimulator for Restless Legs SyndromeFood and Drug Administration
26 Jun 2026Medical Devices; General Hospital and Personal Use Devices; Classification of the Infant Supine Sleep SystemFood and Drug Administration

Rules are matched to sector, not to company. Recent activity in a sector is context rather than a signal about this business — until rules are matched to what a company actually builds, the section is shown as context and nothing more.

Sources

Federal grants from SBIR/STTR, NIH, NSF and DoD records. Federal contracts from USAspending.gov. Private capital from SEC Form D. Patents from USPTO. Publications from OpenAlex. Regulatory activity from the Federal Register. Press matched on company name.

How to read this page

Figures show associations in public records, not causes or predictions. Nothing here is investment advice. An em-dash means no record was found under this company's name, not that none exists.

Data freshness

SEC Form D filings through Oct 23, 2026. SBIR and STTR awards through Oct 21, 2026.